Who has invested in Osivax?

Meiji Seika Pharma Co., Ltd, Noshaq, Anaxago are named among the investors backing Osivax.

Osivax Funding: $42M Raised, Series B (2025)

Osivax funding overview

Osivax is based in Lyon, France. Osivax has raised $42M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in March 2025. The round record for Osivax runs through 2025; nothing later has been disclosed. Investors on record include Meiji Seika Pharma Co., Ltd, Noshaq, Anaxago. 3 distinct backers are named across the disclosed rounds.

Osivax at a glance

Total raised: $42M
Latest round: Series B
Latest round date: March 2025
Headquarters: Lyon, France
Notable investors: Meiji Seika Pharma Co., Ltd, Noshaq, Anaxago

Frequently asked about Osivax funding

How much has Osivax raised?: Osivax has raised $42M in total disclosed funding across the rounds on record.
Who has invested in Osivax?: Meiji Seika Pharma Co., Ltd, Noshaq, Anaxago are named among the investors backing Osivax.
What was the latest Osivax funding round?: The most recent disclosed round is a Series B, announced in March 2025.
Where is Osivax based?: Osivax is based in Lyon, France.
When did Osivax last raise?: The last disclosed Osivax round closed in March 2025 at Series B.

We update the Osivax record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Lyon and their backers are listed below.

Osivax Funding: $42M Raised, Series B (2025)

Osivax funding overview

Osivax at a glance

Frequently asked about Osivax funding

Companies related to Osivax (18)

Browse related funding lists (3)